Biotechnology

Techseriesinsight > Blog > News > Biotechnology

June 13, 2025
PRNewswire
Biotechnology

Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc....

June 12, 2025
PRNewswire
Biotechnology

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse...

June 12, 2025
PRNewswire
Biotechnology

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra’s next-generation biotherapeutic pipeline for immune-mediated...

June 11, 2025
PRNewswire
Biotechnology

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable...

June 9, 2025
PRNewswire
Biotechnology

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical...

June 9, 2025
PRNewswire
Biotechnology

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote “FOR”...

June 2, 2025
PRNewswire
Biotechnology

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer,...

May 30, 2025
PRNewswire
Biotechnology

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it...

May 30, 2025
PRNewswire
Biotechnology

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and...

May 29, 2025
PRNewswire
Biotechnology

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson’s Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Biohaven Ltd. (NYSE: BHVN) (“Biohaven”), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases,...